Williams Peter Bennett
Known title: SVP & CSCMOCIK: 0001781553
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Transaction History
| FLNC | ▲ Buy | Option Exercise | 8,588 | $0 | 7/17/2026 | View on chart |
| FLNC | ▼ Sell | Tax Withholding | 3,905 | $55K | 7/17/2026 | View on chart |
| FLNC | ▲ Buy | Option Exercise | 5,825 | — | 12/18/2025 | View on chart |
| FLNC | ▼ Sell | Tax Withholding | 2,643 | $51K | 12/18/2025 | View on chart |
| FLNC | ▲ Buy | Option Exercise | 4,104 | — | 12/8/2025 | View on chart |
| FLNC | ▼ Sell | Tax Withholding | 1,862 | $43K | 12/8/2025 | View on chart |
| FLNC | ▲ Buy | Option Exercise | 8,588 | $0 | 7/17/2025 | View on chart |
| FLNC | ▼ Sell | Tax Withholding | 3,887 | $32K | 7/17/2025 | View on chart |
| FLNC | ▲ Buy | Option Exercise | 4,104 | — | 12/8/2024 | View on chart |
| FLNC | ▼ Sell | Tax Withholding | 1,793 | $30K | 12/8/2024 | View on chart |
| FLNC | ▲ Buy | Option Exercise | 8,589 | — | 7/17/2024 | View on chart |
| FLNC | ▼ Sell | Tax Withholding | 3,416 | $58K | 7/17/2024 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 119 | $32K | 7/22/2022 | View on chart |
| ROG | ▲ Buy | Grant | 2,670 | $0 | 2/16/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 222 | $60K | 2/12/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 239 | $65K | 2/10/2022 | View on chart |
| ROG | ▼ Sell | Tax Withholding | 658 | $180K | 2/9/2022 | View on chart |
| ROG | ▲ Buy | Grant | 1,662 | $0 | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Fluence Energy Shares Show Mixed Weekly Movement
Fluence Energy stock experienced a sharp drop in one session followed by a rise in another, reflecting the high volatility typical of the company. These moves occurred alongside similar actions in other industrial and energy sector peers. The stock remains well below its 52-week high, indicating continued price pressure despite recent fluctuations.
Fluence Energy Shares Show Mixed Weekly Movement. Fluence Energy stock experienced a sharp drop in one session followed by a rise in another, reflecting the high volatility typical of the company. These moves occurred alongside similar actions in other industrial and energy sector peers. The stock remains well below its 52-week high, indicating continued price pressure despite recent fluctuations.